Development and characterization of a first-in-class small molecule inhibitor of PELP1

被引：0

作者：

Altwegg, Kristin A. ^{[1
]}

Viswanadhapalli, Suryavathi ^{[1
]}

Mann, Monica ^{[1
]}

Pratap, Uday P. ^{[1
]}

Li, Mengxing ^{[1
]}

Liu, Junhao ^{[1
]}

Luo, Yiliao ^{[1
]}

Sareddy, Gangadhara R. ^{[1
]}

Vankayalapati, Hariprasad ^{[2
]}

Vadlamudi, Ratna K. ^{[1
]}

机构：

[1] UT Hlth San Antonio, San Antonio, TX USA

[2] Huntsman Canc Inst, Salt Lake City, UT USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P3-10-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3-10-01

引用

页数：2

共 50 条

[31] First-in-class: RGS protein inhibitor
Kimple, A. J.
Siderovski, D. P.
MOLECULAR INTERVENTIONS, 2007, 7 (01) : 9 - 9
[32] The discovery and preclinical characterization of AMG 176: A first-in-class Mcl-1 inhibitor in clinical development for multiple myeloma
Hughes, Paul E.
CANCER RESEARCH, 2017, 77
[33] Discovery of a first-in-class ERK 1,2 inhibitor
Samatar, Ahmed A.
MOLECULAR CANCER RESEARCH, 2014, 12
[34] Lenacapavir: a first-in-class HIV-1 capsid inhibitor
Dvory-Sobol, Hadas
Shaik, Naveed
Callebaut, Christian
Rhee, Martin S.
CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 15 - 21
[35] Fostemsavir: a first-in-class HIV-1 attachment inhibitor
Grant, Philip M.
Kozal, Michael J.
CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 32 - 35
[36] Discovery and validation of biomarkers to support clinical development of NXP800: A first-in-class orally active, small-molecule HSF1 pathway inhibitor
Workman, P.
Clarke, P. A.
Poele, R. Te
Powers, M.
Box, G.
De Billy, E.
Brandon, A. De Haven
Hallsworth, A.
Hayes, A.
McCann, H.
Sharp, S.
Valenti, M.
Raynaud, F. I.
Eccles, S. A.
Cheeseman, M.
Jones, K.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S35 - S35
[37] Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex
Azaro Pedrazzoli, A. B.
Perez Garcia, J. M.
Cortes, J.
Lopez Miranda, E.
Colombo, I.
Garralda, E.
Hess, D.
Nuciforo, P. G.
Vivancos, A.
Ferrarotto, R.
Schoenborn-Kellenberger, O.
Jorga, K.
Vigolo, M.
Beni, L.
Lehal, R.
Murone, M.
Bauer, M.
Pisa, P.
Vogl, F. D.
Stathis, A.
ANNALS OF ONCOLOGY, 2020, 31 : S484 - S485
[38] In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
Grillo, Mark P.
Erve, John C. L.
Dick, Ryan
Driscoll, James P.
Haste, Nicole
Markova, Svetlana
Brun, Priscilla
Carlson, Timothy J.
Evanchik, Marc
XENOBIOTICA, 2019, 49 (06) : 718 - 733
[39] The Effect of First-in-Class Small Molecule RhoA Inhibitor, HL07, on the Phenylephrine-induced Artery Contraction
Zhang, Yan
Deng, Jing
Ma, Sheng
Xue, Lin
Zhu, Jin
Zhu, Wei-liang
Jiang, Hua-liang
Li, Jian
Miao, Li-yan
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (27) : 4258 - 4264
[40] Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia
Wang, Eunice S.
Frankfurt, Olga
Orford, Keith William
Bennett, Mark
Flinn, Ian W.
Maris, Michael
Konopleva, Marina
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →